3
ALL3
BiospliceYear
3
ALL1
20241
20221
2021DEALS // DEV.
3
ALL1
Deals2
DevelopmentsCountry
3
ALL3
U.S.A3
ALL2
Inapplicable1
The Division of Cancer Treatment and DiagnosisTherapeutic Area
3
ALL3
OncologyStudy Phase
3
ALL3
Phase IDeal Type
3
ALL1
Collaboration2
InapplicableProduct Type
3
ALL3
Other Small MoleculeDosage Form
3
ALL1
Oral1
Oral Tablet1
UndisclosedLead Product
3
ALL3
CirtuvivintTarget
3
ALL3
CLK/DYRKLead Product(s) : Cirtuvivint
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : Undisclosed
Deal Type : Collaboration
Biosplice Begins AML and MDS Trials Sponsored By National Cancer Institute
Details : The collaboration aims for Biosplice to expand its clinical candidate, SM08502 (cirtuvivint), as a standalone treatment and combination therapy in patients with AML and MDS.
Product Name : SM08502
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 09, 2024
Lead Product(s) : Cirtuvivint
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cirtuvivint
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cirtuvivint (SM08502) is a small-molecule inhibitor of the CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases that are emerging as key contributors to numerous forms of cancer.
Product Name : SM08502
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2022
Lead Product(s) : Cirtuvivint
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cirtuvivint,Abiraterone Acetate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
Details : Cirtuvivint is a small-molecule inhibitor of the CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases that are emerging as key contributors to numerous forms of cancer.
Product Name : SM08502
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Cirtuvivint,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable